Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia

References

• Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51(Suppl):39–50.
   PubMedGoogle Scholar
• Ng CH, Kato T, Han C, et al. Definition of treatment-resistant depression - Asia Pacific perspectives. J Affect Disord. 2019;245:626–636. doi:10.1016/j.jad.2018.11.03830445388
   PubMed Web of Science ®Google Scholar
• Ervasti J, Vahtera J, Pentti J, et al. Depression-related work disability: socioeconomic inequalities in onset, duration and recurrence. PLoS One. 2013;8(11):e79855. doi:10.1371/journal.pone.007985524278194
   PubMed Web of Science ®Google Scholar
• Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512–522. doi:10.1016/j.clinthera.2012.09.00123490291
   PubMed Web of Science ®Google Scholar
• Mahlich J, Tsukazawa S, Wiegand F. Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study. Drugs Real World Outcomes. 2018;5(1):35–43. doi:10.1007/s40801-017-0126-529185233
   PubMedGoogle Scholar
• Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459. doi:10.1007/s11920-007-0061-318221624
   PubMedGoogle Scholar
• Fife D, Feng Y, Wang MY, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277–283. doi:10.1016/j.psychres.2017.03.00628288438
   PubMed Web of Science ®Google Scholar
• Kim N, Cho SJ, Kim H, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea. PLoS One. 2019;14(8):e0221552. doi:10.1371/journal.pone.022155231442296
   PubMed Web of Science ®Google Scholar
• Pérez-Wehbe AI, Perestelo-Pérez L, Bethencourt-Pérez JM, Cuéllar-Pompa L, Peñate-Castro W. Treatment-resistant depression: a systematic review of systematic reviews. Int J Clin Health Psychol. 2014;14(2):145–153. doi:10.1016/S1697-2600(14)70048-1
   Web of Science ®Google Scholar
• McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. doi:10.1016/j.jad.2013.10.04324314926
   PubMed Web of Science ®Google Scholar
• Thase M, Connolly KR Unipolar depression in adults: treatment of resistant depression; 2015 Available from: https://www.uptodate.com/contents/unipolar-depression-in-adults-choosing-treatment-for-resistant-depression. Accessed 1124, 2019.
   Google Scholar
• Stata Statistical Software: release 15 [computer program]. College Station, TX: StataCorp LLC; 2017.
   Google Scholar
• QSR International. NVivo Qualitative Data Analysis Software. 11th ed. QSR International Pty Ltd.; 2017.
   Google Scholar
• Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385.23879318
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525.25969470
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults (updated edition); 2010.
   Google Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179–200. doi:10.1016/S0193-953X(05)70283-58827185
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):5–9.
   PubMedGoogle Scholar
• Liu CY, Yeh TL, Chen CS, et al. Treatment Guideline for Major Depressive Disorder in Primary Care. Taipei: Taiwan Association Against Depression; 2012.
   Google Scholar
• Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol. 2012;32(1):114–119. doi:10.1097/JCP.0b013e31823f705d22198447
   PubMed Web of Science ®Google Scholar
• Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res. 2015;66–67:84–94. doi:10.1016/j.jpsychires.2015.04.020
   PubMed Web of Science ®Google Scholar
• Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA Psychiatry. 2017;318(2):132–145.
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder; 2010 Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed 1118, 2019.
   Google Scholar
• Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704. doi:10.1016/j.biopsych.2007.08.01017919460
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836–1855. doi:10.4088/JCP.v67n120317194261
   PubMed Web of Science ®Google Scholar
• Fang Y, Yuan C, Xu Y, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol. 2011;31(5):638–642.21869688
   PubMed Web of Science ®Google Scholar
• Bauer M, Dell’osso L, Kasper S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord. 2013;151(1):209–219. doi:10.1016/j.jad.2013.05.07923810357
   PubMed Web of Science ®Google Scholar
• Carter B, Strawbridge R, Husain MI, et al. Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis. Int Rev Psychiatry. 2020;32(5–6):477–490. doi:10.1080/09540261.2020.176574832498577
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Carter B, Marwood L, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry. 2019;214(1):42–51. doi:10.1192/bjp.2018.23330457075
   PubMed Web of Science ®Google Scholar
• Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19(5):427–434. doi:10.1097/00004714-199910000-0000610505584
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151(9):1372–1374.8067495
   PubMed Web of Science ®Google Scholar
• Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996;16(4):307–314. doi:10.1097/00004714-199608000-000068835706
   PubMed Web of Science ®Google Scholar
• Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269–275. doi:10.1016/j.jad.2014.05.05325069082
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. West-Ward Pharmaceuticals. Lithium and Lithium carbonate [package insert]; 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/017812s034,018421s033,018558s028lbl.pdf. Accessed 217, 2020.
   Google Scholar
• Treuer T, Liu CY, Salazar G, et al. Use of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisited. Asia Pac Psychiatry. 2013;5(4):219–230. doi:10.1111/appy.1209023857712
   PubMed Web of Science ®Google Scholar
• Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. Can J Psychiatry. 2016;61(1):29–43. doi:10.1177/070674371562041127582451
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43–64. doi:10.2165/11587620-000000000-0000021175239
   PubMed Web of Science ®Google Scholar
• Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487–e498. doi:10.4088/JCP.14r0920425919841
   PubMed Web of Science ®Google Scholar
• Janssen. Janssen announces U.S. FDA approval of SPRAVATO™ (esketamine) CIII nasal spray for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief; 2019 Available from: https://www.janssen.com/janssen-announces-us-fda-approval-spravato-esketamine-ciii-nasal-spray-adults-treatment-resistant. Accessed 1123, 2019.
   Google Scholar
• European Medicines Agency. Spravato: EPAR - product information; 2019 Available from: https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf. Accessed 1015, 2020.
   Google Scholar
• U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs (SPRAVATO); 2019 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf. Accessed 1015, 2020.
   Google Scholar
• Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression - First FDA-approved antidepressant in a new class. N Engl J Med. 2019;381(1):1–4. doi:10.1056/NEJMp190330531116916
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Janssen Pharmaceuticals. SPRAVATO™ (esketamine) nasal spray, CIII [package insert]; 2019 Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf. Accessed 217, 2020.
   Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438. doi:10.1176/appi.ajp.2019.1902017231109201
   PubMed Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. doi:10.1001/jamapsychiatry.2019.118931166571
   PubMed Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. doi:10.1001/jamapsychiatry.2017.008028249076
   PubMed Web of Science ®Google Scholar
• Szarmach J, Cubała WJ, Włodarczyk A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub. 2019;31(Suppl 3):585–590.31488795
   PubMedGoogle Scholar
• Włodarczyk A, Cubała WJ, Szarmach J, Małyszko A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. Psychiatr Danub. 2019;31(Suppl 3):530–533.31488786
   PubMedGoogle Scholar
• Liang HJ, Ungvari GS, Lee TSH, Tang WK. Ketamine addiction. Dual Diagn Open Access. 2018;3:3. doi:10.21767/2472-5048.100037
   Google Scholar
• Feng LY, Wada K, Chung H, Han E, Li JH. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan. Kaohsiung J Med Sci. 2019.
   Web of Science ®Google Scholar
• Tan TB, Nandhakumar G Ketamine antidepressant: breakthrough or potential hazard?; 2018 Available from: https://www.rsis.edu.sg/wp-content/uploads/2018/03/CO18044.pdf. Accessed 1123, 2019.
   Google Scholar
• Li JH, Kasinather V, Cheung YW, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil. 2011;2:11–20. doi:10.2147/SAR.S1545824474851
   PubMedGoogle Scholar
• Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882. doi:10.1371/journal.pone.007688224204694
   PubMed Web of Science ®Google Scholar
• Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: A meta-analysis. Hum Psychopharmacol. 2009;24(5):401–408. doi:10.1002/hup.103319526453
   PubMed Web of Science ®Google Scholar
• Glue P, Donovan MR, Kolluri S, Emir B. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry. 2010;44(8):697–705. doi:10.3109/0004867100370544120636190
   PubMed Web of Science ®Google Scholar
• Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661. doi:10.1016/S0140-6736(03)12599-812606176
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting February 12; 2019 Available from: https://www.fda.gov/media/121376/download. Accessed 1124, 2019.
   Google Scholar
• National Institute for Health and Care Excellence - Depression: the treatment and management of depression in adults; 2009 Available from: https://www.nice.org.uk/guidance/cg90/documents/depression-in-adults-update-full-guideline-prepublication2. Accessed 1124, 2019.
   Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/070674371665941727486148
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med. 2001;Spec No Pharmacotherapy:1–86.
   Google Scholar
• Kok RM, Reynolds CF 3rd. Management of depression in older adults: a review. JAMA. 2017;317(20):2114–2122. doi:10.1001/jama.2017.570628535241
   PubMed Web of Science ®Google Scholar
• Leiknes KA, Jarosh-von Schweder L, Hoie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283–344. doi:10.1002/brb3.3722741102
   PubMed Web of Science ®Google Scholar
• Hemphill R, Walter W, Grey J. The treatment of mental disorders by electrically induced convulsions. Br J Psychiatry. 1941;87(367):256–275.
   Google Scholar
• Chanpattana W, Kramer BA, Kunigiri G, Gangadhar BN, Kitphati R, Andrade C. A survey of the practice of electroconvulsive therapy in Asia. J ECT. 2010;26(1):5–10. doi:10.1097/YCT.0b013e3181a7436819444137
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Resource book on mental health, human rights and legislation; 2005 Available from: https://ec.europa.eu/health/sites/health/files/mental_health/docs/who_resource_book_en.pdf. Accessed 1124, 2019.
   Google Scholar
• Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523. doi:10.1177/070674371665941627486151
   PubMed Web of Science ®Google Scholar
• Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatry. 2016;61(9):561–575. doi:10.1177/070674371666003327486154
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence - Depression in adults: recognition and management; 2018 Available from: https://www.nice.org.uk/guidance/cg90. Accessed 1124, 2019.
   Google Scholar
• Baghai TC, Moller HJ. Electroconvulsive therapy and its different indications. Dialogues Clin Neurosci. 2008;10(1):105–117.18472488
   PubMedGoogle Scholar
• Sackeim HA, Decina P, Kanzler M, Kerr B, Malitz S. Effects of electrode placement on the efficacy of titrated, low-dose ECT. Am J Psychiatry. 1987;144(11):1449–1455.3314538
   PubMed Web of Science ®Google Scholar
• Jan Otto Ottosson J, Fink M. Ethics in Electroconvulsive Therapy. New York: Brunner-Routledge; 2004.
   Google Scholar
• Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244–253. doi:10.1097/00124509-200112000-0000311731725
   PubMed Web of Science ®Google Scholar
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808. doi:10.1016/S0140-6736(03)12705-512642045
   PubMed Web of Science ®Google Scholar
• Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20(1):13–20. doi:10.1097/00124509-200403000-0000415087991
   PubMed Web of Science ®Google Scholar
• Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT. 2003;19(3):139–147. doi:10.1097/00124509-200309000-0000512972983
   PubMed Web of Science ®Google Scholar
• Schutter DJ. Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorder. Psychol Med. 2010;40(11):1789–1795. doi:10.1017/S003329171000005X20102670
   PubMed Web of Science ®Google Scholar
• Berlim MT, Van den Eynde F, Jeff Daskalakis Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology. 2013;38(4):543–551. doi:10.1038/npp.2012.23723249815
   PubMed Web of Science ®Google Scholar
• Berlim MT, Van den Eynde F, Daskalakis ZJ. A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychol Med. 2013;43(11):2245–2254. doi:10.1017/S003329171200280223200131
   PubMed Web of Science ®Google Scholar
• McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):35–48. doi:10.4088/JCP.16cs10905
   Web of Science ®Google Scholar
• Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010;71(7):873–884. doi:10.4088/JCP.08m04872gre20361902
   PubMed Web of Science ®Google Scholar
• Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depress Anxiety. 2013;30(7):614–623. doi:10.1002/da.2206023349112
   PubMed Web of Science ®Google Scholar
• Ontario HQ. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser. 2016;16(5):1–66.
   Google Scholar
• Muller HHO, Moeller S, Lucke C, Lam AP, Braun N, Philipsen A. Vagus nerve stimulation (VNS) and other augmentation strategies for therapy-resistant depression (TRD): review of the evidence and clinical advice for use. Front Neurosci. 2018;12:239. doi:10.3389/fnins.2018.0023929692707
   PubMed Web of Science ®Google Scholar
• Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2018;5:CD010558.29761488
   PubMed Web of Science ®Google Scholar
• de Maat SM, Dekker J, Schoevers RA, de Jonghe F. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. Eur Psychiatry. 2007;22(1):1–8. doi:10.1016/j.eurpsy.2006.10.00817194571
   PubMed Web of Science ®Google Scholar
• Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70(9):1219–1229. doi:10.4088/JCP.09r0502119818243
   PubMed Web of Science ®Google Scholar
• Bauer M, Severus E, Kohler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder - Update 2015. World J Biol Psychiatry. 2015;16(2):76–95. doi:10.3109/15622975.2014.100178625677972
   PubMed Web of Science ®Google Scholar
• Bennabi D, Charpeaud T, Yrondi A, et al. Clinical guidelines for the management of treatment-resistant depression: french recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry. 2019;19(1):262. doi:10.1186/s12888-019-2237-x31455302
   PubMed Web of Science ®Google Scholar
• Zhang Q, DiBernardo A, Heerlein K, et al. Association of treatment resistant depression with healthcare resource utilization and physician satisfaction with disease management. Value Health. 2018;21:S188. doi:10.1016/j.jval.2018.04.1270
   Web of Science ®Google Scholar